Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters

Shiho Fujiwara1, Naoko Wada1, Yawara Kawano1, Yutaka Okuno1, Yoshita Kikukawa1, Shinya Endo1, Nao Nishimura1, Nina Ueno1, Hiroaki Mitsuya1 and Hiroyuki Hata1,2*

Abstract

Background: Lactate levels within tumors are correlated with metastases, tumor recurrence, and radioresistance, thus apparently contributing to poor outcomes in patients with various cancers. We previously reported that high-level production of lactate by multiple myeloma (MM) cell lines is associated with high-level LDH activity within such MM cells. However, the kinetics of lactate remains to be studied. In the present study, we attempted to elucidate the mechanism of lactate incorporation into MM cells.

Methods: Six MM cell lines and stromal cells obtained through long-term culture of bone marrow samples from MM patients were employed. Incorporation of lactate was quantified using C14-labeled lactate. The role of MCT1, a member of the monocarboxylate transporters (MCTs), expressed on MM cells, was examined in the presence of its inhibitor (α-cyano-4-hydroxycinnamic acid: CHC) and using gene-silencing technique.

Results: MM cell lines as well as stromal cells were found to produce lactate. Incorporation of C14-labeled lactate into MM cells occurred in all 6 MM cell lines analyzed. Inhibition of MCT1 by using CHC or MCT1-targeting siRNA reduced lactate incorporation and caused apoptosis in MM cells. This apoptosis was enhanced when the activity of pyruvate dehydrogenase kinase was blocked by dichroloacetate. Survival of normal peripheral blood mononuclear cells was not influenced by MCT1 inhibition.

Conclusions: The present data suggest that lactate is produced by MM cell lines and stromal cells, and contributes to the survival of such MM cells in autocrine or paracrine manners. Suppression of lactate incorporation by targeting MCT1 may provide a novel therapeutic strategy for MM which may be applicable for other B-cell neoplasms.

Keywords: Multiple myeloma, Glucose, Lactate, Monocarboxylate transporters

Background

It has been reported that the growth of certain cancer cells is dependent on aerobic glycolysis to obtain ATP efficiently via glycolysis under hypoxic conditions, ultimately leading to the production of lactate by cancer cells [1]. It has also been reported that elevated lactate levels within tumors are correlated with the incidence of metastases [2,3], tumor recurrence, radioresistance [4], and poor prognosis [5].

Lactate is transported through monocarboxylate transporters (MCTs), which are composed of 14 members and encoded by the SLC16 gene family. Among the MCTs, only four isoforms (MCT1–MCT4) are known as proton-linked transporters. MCT1 has a superior affinity for lactate compared with MCT4, and therefore MCT1 is considered to facilitate lactate uptake, whereas MCT4 is considered to export lactate from inside cells [5-8]. The functional expressions of MCT1 and MCT4 are regulated by CD147 (basigin), which is essential for trafficking and anchoring MCTs in plasma membranes [9-11]. MCT1 is expressed in most tissues and various cancer cells (e.g., colon, breast, lung, prostate, stomach) [5,12].
and MCT1 inhibition decreases the intracellular pH, resulting in cell death [13].

We previously reported that genes related to aerobic glycolysis are upregulated in MM cells, and that myeloma cells produce large amounts of lactate in correlation with expression of the LDH gene [14]. However, accumulating evidence indicates that lactate produced by cancer cells is incorporated into the cancer cells themselves as a fuel for oxidative phosphorylation [15,16]. Doherty et al. [16] et al. reported that lactate is produced by stromal cells and supplied to oxidative cancer cells, which is known as the reverse Warburg effect. Similar finding was reported in diffuse large B-cell lymphoma by Martinez et al., showing that production of lactate from lymphoma associated stroma cells and lactate incorporation to lymphoma cells [17]. These previous reports strongly indicate that lactate is not an energy waste, but instead is actively incorporated into cells and contributes to the survival of solid tumors or B-cell neoplasms. However, to date, there have been no reports showing the incorporation of lactate into myeloma cells. Thus, in the present study, we investigated the kinetics of lactate in myeloma cells and its importance for the survival of myeloma cells.

Results

Expression of lactate transporters and lactate incorporation into MM cells

Expressions of MCT1 and CD147 were detected at various levels in myeloma cell lines by western blotting (Figure 1A and B). Analyses of lactate incorporation into myeloma cells showed that lactate was indeed incorporated into all myeloma cell lines at various levels (Figure 1C).

Next, we analyzed how lactate was incorporated into myeloma cells. To elucidate the contribution of MCT1 to lactate incorporation, the expressions of MCT1 or CD147 were inhibited by siRNA transfection (Figure 2A and B). MCT1 knockdown led to a significant reduction in lactate incorporation, while CD147 knockdown did not result in a reduction in lactate incorporation (Figure 2C), suggesting a contribution of MCT1 to lactate incorporation into myeloma cells.

MCT1 inhibition induces apoptosis

Because we found that lactate was incorporated into myeloma cells, we hypothesized that incorporated lactate may serve as an energy resource for myeloma cells, and therefore that myeloma cells may undergo apoptosis when there is a shortage of lactate within the cells. To prove this hypothesis, we used CHC, a competitive inhibitor of MCT1, to investigate whether it induces apoptosis in myeloma cell lines by inhibiting lactate incorporation. As expected, CHC induced apoptosis in a dose-dependent manner (Figure 3A). However, CHC did not show cytotoxicity toward normal peripheral blood mononuclear cells (PBMCs) (Figure 3B). We confirmed the cytotoxic activity of CHC toward myeloma cells isolated from MM patients and found significant induction of apoptosis by CHC (Figure 3C). Subsequently, we utilized MCT1-knockdown cells to further confirm the role of MCT1 in the survival of myeloma cells. As shown in Figure 3D, significant induction of apoptosis was found upon MCT1 mRNA inhibition. However, CD147 knockout did not contribute to apoptosis (data not shown).

Increased cytotoxic effect of CHC with a glycolysis inhibitor

Next, we investigated the effect of combined treatment of DCA, which theoretically reduces lactate production by inhibiting pyruvate dehydrogenase kinase, with CHC. We considered that the combination of DCA with CHC should accelerate lactate reduction within myeloma cells and eventually lead to enhancement of apoptosis. As expected, this combined treatment caused a significant increase in apoptosis in the myeloma cell line KMM-1 (Figure 4).

Discussion

We previously reported that aerobic glycolysis is operational in myeloma cells [14] and observed that significant amounts of lactate were produced by myeloma cells as a result of glycolysis. However, lactate is not a wasted metabolite, but can be considered as an important energy source for cancer cells [6,15,16,18,19]. Doherty et al. [16] reported that lactate is supplied to cancer cells from the surrounding environment, and referred to this phenomenon as the reverse Warburg effect. We have shown that lactate was clearly incorporated into myeloma cells and that this incorporation was mediated by MCT1. We also observed production of lactate by bone marrow stromal cells (data not shown), suggesting that the reverse Warburg effect might be applied to the microenvironment in MM as previously reported in B-cell lymphoma [17]. Taking these hypotheses together, we further suggest that lactate may serve as an autocrine energy resource, because it is both produced and incorporated by myeloma cells (Figure 5).

However, the mechanisms that regulate lactate kinetics are still not well established. We found that CD147 knockdown did not influence lactate uptake or induce apoptosis, suggesting that CD147 is not required for lactate kinetics. Additionally, we found that MCT1 knockdown decreased lactate uptake, and thus consider that lactate is incorporated by MCT1, but not through CD147. However, other investigators reported that both CD147 and MCT1 are responsible for proliferation of myeloma cells and exportation of lactate [13], suggesting that the exact roles of these molecules in lactate transport remain controversial.

Given the accumulation of reports showing MCT1 expression in various cancer cells (e.g. breast, colon, and lung cancer) and its correlation with poor prognosis
[2,3,5,20,21], these previous reports indicate that MCT1 should play an important role for the survival of myeloma cells. Walters et al. [13] also reported that MCT1 mRNA expression levels were significantly higher in MM plasma cells than MGUS plasma cells, and that MCT1 expression was correlated with resistance to chemotherapy. Because MCT1 was reported to be regulated by c-Myc in some cancer cells [22-25], and MYC dysregulation was caused by complex translocation or insertion as a late progression event in MM, MCT1 could be induced in advanced MM under the control of c-Myc. Given that MCT1 could be an adverse prognostic factor, we consider that MCT1 could be a good therapeutic target for advanced MM.

CHC, a competitive inhibitor for MCT1, was reported to show anticancer effects in various cancer cells [15,26-28]. In a previous report, CHC was found to inhibit mitochondrial respiration and decrease cell growth through inhibition of cellular pyruvate uptake [29]. Zhao et al. [26] reported that CHC suppressed tumor growth of osteosarcoma in vitro and in vivo through regulation of the NF-kB pathway. Moreover, they reported that CHC enhanced the efficacy of conventional chemotherapeutic agents. Another report showed that CHC contributed to chemosensitization against cisplatin in a colon cancer cell line [28]. However, there are no reports showing antitumor effects of CHC for myeloma cells. In this study, CHC induced apoptosis in myeloma cells, but did not exhibit cytotoxicity toward normal PBMCs, indicating that MCT1 could be a safe therapeutic candidate molecule. Moreover, because we found augmentation of cytotoxicity by CHC with DCA, cooperative inhibition of the glucose metabolic pathway could be a useful option.

Our results indicate that modification of lactate kinetics, such as targeting of MCTs by antibody-based chemotherapeutic reagents, could be an attractive modality to control the growth of myeloma cells although the target of this modality may be limited for some subsets of
MM cases in which MM cells are depending on Reverse Warburg Effect. Because lactate does not seem to provide to a large contribution for resting normal cells, this modality should provide efficacy that is relatively specific to cancer cells with minimal toxic effects toward normal tissues.

**Conclusions**

We present here that lactate is produced by MM cell lines and stromal cells, and contributes to the survival of such MM cells in autocrine or paracrine manners. Lactate incorporation is dependent on MCT1. Suppression of lactate incorporation by targeting MCT1 may provide a novel therapeutic strategy for MM.

**Materials and methods**

**Cells and cell culture**

Human myeloma cell lines KMS-12BM (12BM) [30], KMS-12PE (12PE) [30], U266 [31], RPMI8226 [32], KMM-1 [33], and KHM11 [34] were cultured in RPMI-1640 containing 10% FBS at 37°C under 5% CO2. Usage of isolated myeloma cells from bone marrow samples were approved by Ethical Committee of Kumamoto University.

**Inhibitors**

Dichloroacetate (DCA) and α-cyano-4-hydroxycinnamic acid (CHC) were purchased from Sigma-Aldrich (St Louis, MO, USA), and dissolved in phosphate-buffered saline and dimethyl sulfoxide (DMSO), respectively.

**Measurement of lactate**

Lactate concentrations were evaluated using a lactate meter (Lactate Pro2; Arkray, Kyoto, Japan), which electronically analyzed potassium ferrocyanide converted from ferricyanide by lactate.
Figure 3 (See legend on next page.)
cDNA synthesis and real-time PCR
RNA was extracted from myeloma cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). cDNA synthesis was performed using a SuperScript First-Standard Synthesis System (Invitrogen) according to the manufacturer’s protocol. Quantitative PCR analyses were performed with Assay-on-Demand primers and Taqman Universal PCR Master Mix Reagent (Applied Biosystems, Foster City, NJ, USA). The samples were analyzed using an ECO™ Real-Time PCR System (Illumina, San Diego, CA, USA). The ΔΔCt method was employed to analyze the relative changes in gene expression as previously described [35], with ACTB as a normalization control. The following primers were used to quantify the expression of MCT1 and actin, respectively: SLC16A1 (Hs00161826_m1); and ACTB (Hs99999903_m1).

Western blot analysis
Cell lysates were prepared using M-PER Mammalian Protein Extraction Reagent (Pierce Biotechnology Inc., Rockford, IL, USA) after addition of Halt EDTA-free phosphatase inhibitor cocktail and Halt protease inhibitor cocktail (both from Pierce Biotechnology Inc.). Quantification of total protein was performed with a Pierce BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA), and equal amounts of protein were used for analysis. The cell lysates were separated in NuPAGE Bis-Tris precast gels (Invitrogen) and transferred to PVDF membranes. The membranes were blocked with 5% non-fat dry milk dissolved in Tris-buffered saline (TBS) containing 0.5% Tween-20 (TBS-T) for 1 h at room temperature, and then incubated with primary antibodies at 4°C for 18 h. The following primary antibodies were used: anti-MCT1...
were performed using Hiperfect Transfection Reagent (Qiagen) according to the manufacturer’s protocol. Briefly, \( 2 \times 10^5 \) KMM-1 cells in 100 \( \mu \)L of medium were seeded into 24-well plates and transfected with 750 ng of siSLC16A1 or control siRNA.

**Lactate uptake assay**

On day 2 after siRNA transfection, KMM-1 cells were incubated in uptake buffer (10 mM HEPES, 5 mM KCl, 150 mM NaCl, 1 mM MgCl2, pH 7.5) containing \(^{14}\)C-lactate (PerkinElmer, Waltham, MA, USA) for 1 h at 37°C. Uptake was stopped by incubating the cells at 4°C, and the cells were washed twice using 200 \( \mu \)L of uptake buffer. The cells were then lysed in 200 \( \mu \)L of uptake buffer containing 1% SDS and the cell lysates were collected into scintillation vials for quantification of \(^{14}\)C-lactate uptake. To ensure selective incorporation of lactate, some cells were simultaneously treated with \(^{14}\)C-lactate and unlabeled lactate (10 mM).

**Statistical analysis**

The data were analyzed statistically by Student’s \( t\)-test using Statflex version 6 (Artech Co. Ltd., Osaka, Japan). Values of \( p < 0.05 \) were considered statistically significant.

**Abbreviations**

(MM): Multiple myeloma; (MCTs): Monocarboxylate transporters; (CHC): \( \alpha \)-cyano-4-hydroxycinnamic acid; (DCA): Dichloroacetate; (DMSO): Dimethyl sulfoxide; (TBS): Tris-buffered saline.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

SF, NW, and YK performed experiments. YO, YK, SE, NN, and NU collected samples from MM cases. HH and SF conducted and designed the experiments. SF wrote whole manuscript under supervision of HH. HM supervised the experiments. All authors read and approved the final manuscript.

**Acknowledgments**

This work was partly funded by a grant from the Amyloidosis Research Committee from the Ministry of Health, Labour, and Welfare, Japan.

Received: 4 March 2015 Accepted: 2 April 2015

Published online: 21 April 2015

References

1. Kim JW, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927–30. doi:10.1158/0008-5472.CAN-06-1501.

2. Breslin DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51:349–53.

3. Walenta S, Wetterling M, Lehnke M, Schwikert G, Sundfor K, Roftstad EK, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000;60:916–21.

4. Quennet V, Yaromina A, Zips D, Rosner A, Walenta S, Baumann M, et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol. 2006;81:130–5. doi:10.1016/j.radonc.2006.08.012.
5. Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol. 2016;12:477–488. doi:10.2217/fon.15.94.
6. Dioai N, Feron O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Model Mech. 2011;4:272–282. doi:10.1242/dmm.007724.
7. Halestrap AP. The monocarboxylate transporter family—Structure and functional characterization. IUBMB Life. 2012;64:1–9. doi:10.1002/iub.573.
8. Halestrap AP, Meredith D. The SLC16 gene family from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch. 2004;447:19–28. doi:10.1007/s00424-003-0657-2.
9. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000;19:3896–3904. doi:10.1093/emboj/19.15.3896.
10. Wilson MC, Meredith D, Halestrap AP. Fluorescence resonance energy transfer studies on the interaction between the lactate transporter MCT1 and CD147 provide information on the topology and stoichiometry of the complex in situ. J Biol Chem. 2002;277:3666–3672. doi:10.1074/jbc.M109630200.
11. Nabeshima K, Iwasaki H, Koga K, Hejo H, Suzumuya I, Kikuchi M. Emminpr (basigin/CD147): matrix metalloproteinase modulator and multifunctional cellular receptor that plays a critical role in cancer progression. Pathol Int. 2006;56:359–367. doi:10.1111/j.1440-1827.2006.01972.x.
12. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr. 2012;44:127–139. doi:10.1007/s10863-012-9428-1.
13. Walters DK, Arendt BK, Jelinek DF. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle. 2013;12:3175–3183. doi:10.4161/cc.26193.
14. Fujiwara S, Kawano Y, Yuki H, Okuno Y, Nosaka K, Mitsuya H, et al. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer. 2013;108:170–8. doi:10.1038/bjc.2012.527.
15. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment. Radiother Oncol. 2011;99:404–410. doi:10.1016/j.radonc.2011.05.053.
16. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player paradigm to anti-cancer treatments. Dis Model Mech. 2011;4:727–734. doi:10.1242/dmm.007724.
17. Martinez-Outschoorn UE, Whitaker-Menezes D, Valsecchi M, Martinez-Cantarin M, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol. 2013;15:172–88. doi:10.1093/neuonc/noq298.
18. Kumar A, Kant S, Singh SM. Targeting monocarboxylate transporter by alpha-cyano-4-hydroxycinnamate modulates apoptosis and cisplatin resistance of Colo205 cells: implication of altered cell survival regulation. Apoptosis. 2013;18:1574–85. doi:10.1007/s10495-013-0894-7.
19. Diers AR, Broniwowska KA, Chang CF, Hogg N. Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition. Biochem J. 2012;444:561–571. doi:10.1042/Bj20122094.
20. Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M, Namba M. Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haematol. 1989;73:199–204.
21. Ikeyama S, Nakagawa S, Arakawa M, Sugino H, Kakinuma A. Purification and characterization of IgE produced by human myeloma cell line, U266. Mol Immunol. 1986;23:159–67.
22. Matsuoka Y, Mocre GE, Yagi Y, Pressman D. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med. 1967;125:1246–50.
23. Togawa A, Inoue N, Miyamoto K, Hyodo H, Namba M. Establishment and characterization of a human myeloma cell line (KMM-1). Int J Cancer. 1982;29:4945–500.
24. Hata H, Matsuaki H, Sonoki T, Takemoto S, Kuibayashi N, Nagasaki A, et al. Establishment of a CD45-positive immature plasma cell line from an aggressive multiple myeloma with high serum lactate dehydrogenase. Leukemia. 1994;8:766–73.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. doi:10.1006/meth.2001.1262.